Questions on individual use of a non-authorised pharmaceutical

Can a healthcare facility be specifically penalised for failure to report the use of a non-authorised medicinal product to SÚKL?

Should adverse reactions, if applicable, be reported with the use of non-authorised medicinal products? If so, how should they be reported and to whom, and who will be responsible for the reporting?